The effects of amiodarone on the thyroid
DOI:
https://doi.org/10.23938/ASSN.0132Keywords:
Amiodarona. Hipotiroidismo. TirotoxicosisAbstract
Background. Amiodarone is a drug widely used for the treatment of arrhythmias. In 16% of amiodarone-treated patients it causes changes in the thyroid function. The aim of this study was to determine the importance of amiodarone-induced thyroid dysfunction in the population of Navarre, studied between 2001 and 2007. Methods. We present a retrospective study that considers the characteristics of 182 amiodarone-treated patients with thyroid dysfunction who had been referred to our Institute. We determined a series of biochemical and instrumental investigations (measurement of thyrotrophin, free thyroid hormones and thyroid autoantibodies; thyroid sonography and thyroid scintigraphy uptake). Results. Screening of the thyroid function, recommended before starting amiodarone treatment, was carried out in only 20.9 % of the patients. Forty-one percent of patients developed amiodarone induced hypothyroidism; in 76% of them the drug was withdrawn. Hypothyroidism appears after 21 (± 12) months of amiodarone treatment. Forty-eight point six developed permanent hypothyroidism. This group of patients had higher serum levels of TSH (thyrotropin) and were treated for less time with amiodarone. Fifty-nine percent of patients developed amiodarone induced thyrotoxicosis; 59.4 % were diagnosed with thyrotoxicosis (AIT) type 1, 30.6% AIT type 2 and the remaining 10 % were diagnosed with mixed thyrotoxicosis. Thyrotoxicosis appears after 29.5 (± 17) months of amiodarone treatment. The serum levels of free thyroxine were significantly higher in the AIT type 2 than in the AIT type1. All patients were treated with antithyroid drugs and/or corticoids. Some patients were admitted to hospital due to the severity of their illness. Conclusions. In our study, amiodarone induced thyrotoxicosis was more frequent than hypothyroidism (59% vs 41%) because Navarre is an iodine-deficient area. It is necessary to control the thyroid function after 2-3 years of amiodarone treatment.Downloads
References
1. SHEZAD BASARIA, MD, DAVID S. COOPER, MD. Amiodarone and the thyroid. Am J Med 2005; 118: 706-714.
https://doi.org/10.1016/j.amjmed.2004.11.028
2. IGLESIAS P. Repercusiones del tratamiento con amiodarona sobre la función tiroidea y su manejo actual. Endocrinol Nutr 2007; 54: 354-370.
https://doi.org/10.1016/S1575-0922(07)71465-1
3. HARJAI KJ, LICATA AA. Effects of amiodarone on thyroid function. Ann Intern Med 1997; 126: 63-73.
https://doi.org/10.7326/0003-4819-126-1-199701010-00009
4. GOLDSCHLAGER N, EPSTEIN AE, NACCARELLI G, OLSHANSKY B, SINGH B. Practical guidelines for clinicians who treat patients with amiodarone. Practice Guidelines Subcommittee, North American society of pacing and electrophysiology. Arch Intern Med 2000; 160: 1741-1748.
https://doi.org/10.1001/archinte.160.12.1741
5. ENIO M. BARTALENA L, BOGAZZI F, BRAVERMAN LE. The effects of amiodarone on the thyroid. Endocr Rev 2001; 22: 240-254.
https://doi.org/10.1210/edrv.22.2.0427
6. BOGAZZI F, BARTALENA L, GASPERI M, BRAVERMAN LE, MARTINO E. The various effects of amiodarone on thyroid function. Thyroid 2001; 11: 511-519.
https://doi.org/10.1089/105072501300176471
7. MARTINO E, SAFRAN M, AGHINI-LOMBARDI F, RAJATANAVIN R. LENZIARDI M, FAY M et al. Environmental iodine intake and thyroid dysfunction during chronic amiodarone therapy. Ann Intern Med 1984; 101: 28-34.
https://doi.org/10.7326/0003-4819-101-1-28
8. BASARIA S, COOPER DS. Amiodarone and the thyroid. Am J Med 2005; 118: 706-714.
https://doi.org/10.1016/j.amjmed.2004.11.028
9. FRANKLYN JA, GAMMAGE MD. Treatment of amiodarone-associted thyrotoxicosis. Nat Clin Pract Endocrinol Metab 2007; 3: 662-666.
https://doi.org/10.1038/ncpendmet0592
10. ERDOGAN MF, GÜLEÇ S, TUTAR E, BASKAL N, ERDOGAN G. A stepwise approach to the treatment of amiodarone-induced thyrotoxicosis. Thyroid 2003; 13; 205-209.
https://doi.org/10.1089/105072503321319521
11. PIGA M, COCCO MC, SERRA A, BOI F, LOY M, MARIOTTI S. The usefulness of 99m- Tc-sestaMIBI thyroid scan in the differential diagnosis and management of amiodarone-induced thyrotoxicosis. Eur J Endocrinol 2008; 159: 423-429.
https://doi.org/10.1530/EJE-08-0348
12. EATON SE, EUINTON HA, NEWMAN CM, WEETMAN AP, BENNET WM. Clinical experience of amiodarone-induced thyrotoxicosis over a 3-year period: role of colour-flow Doppler sonography. Clin Endocrinol (Oxf) 2002; 56: 33-38.
https://doi.org/10.1046/j.0300-0664.2001.01457.x
13. TANDA ML, BOGAZZI F, MARTINO E, BARTALENA L. Amiodarone-induced thyrotoxicosis: something new to refine the inicial diagnosis? Eur J Endocrinol 2008; 159: 359-361.
https://doi.org/10.1530/EJE-08-0553
14. MONTEIRO E, GALVAO-TELES A, SANTOS ML, MOURAO L, CORREIA MJ, LOPO TUNA J et al. Antithyroid antibodies as an early marker for thyroid disease induced by amiodarone. Br Med J 1986; 292: 227-228.
https://doi.org/10.1136/bmj.292.6515.227
15. SAFRAN M, MARTINO E, AGHINI-LOMBARDI F, BARTALENA L, BALZANO S, PINCHERA A et al. Effect of amiodarone on circulating antithyroid antibodies. BMJ 1988; 297: 456-457.
https://doi.org/10.1136/bmj.297.6646.456
16. TRIP MD, WIERSINGA W, PLOMP TA. Incidence, predictability, and pathogenesis of amiodarone-induced thyrotoxicosis and hypothyroidism. Am J Med 1991; 91: 507-511.
https://doi.org/10.1016/0002-9343(91)90187-3
17. BATCHER EL, TANG XC, SINGH BN, SINGH SN, REDA DJ, HERSHMAN JM. Thyroid function abnormalities during amiodarona therapy for persistent atrial fibrillation. Am J Med 2007; 120; 880-885.
https://doi.org/10.1016/j.amjmed.2007.04.022
18. SATO K, MIYAKAWA M, ETO M, INABA T, MATSUDA N, SHIGA T el al. Clinical characteristics of amiodarone-induced thyrotoxicosis and hypothyroidism in Japan. Endocr J 1999; 46: 443-451.
https://doi.org/10.1507/endocrj.46.443
19. MARTINO E, AGHINI-LOMBARDI F, MARIOTTI S, BARTALENA L, LENZIARDI M, CECCARELLI C et al. Amiodarone iodine-induced hypothyroidism: risk factors and follow-up in 28 cases. Clin Endocrinol (Oxf) 1987; 26: 227-237.
https://doi.org/10.1111/j.1365-2265.1987.tb00781.x
20. SATO K, MIYAKAWA M, ETO M, INABA T, MATSUDA N, SHIGA T el al. Clinical characteristics of amiodarone-induced thyrotoxicosis and hypothyroidism in Japan. Endocr J 1999; 46: 443-451.
https://doi.org/10.1507/endocrj.46.443
21. HARJAI KJ, LICATA AA. Amiodarone induced hyperthyroidism: a case series and brief review of literature. Pacing Clin Electrophysiol 1996; 19: 1548-1554.
https://doi.org/10.1111/j.1540-8159.1996.tb03179.x
22. BOROWSKI GD, GAROFANO CD, ROSE LI, SPIELMAN SR, ROTMENSCH HR, GREENSPAN AM et al. Effect of long-term amiodarone therapy on thyroid hormone levels and thyroid function. Am J Med 1985; 78: 443-450.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
La revista Anales del Sistema Sanitario de Navarra es publicada por el Departamento de Salud del Gobierno de Navarra (España), quien conserva los derechos patrimoniales (copyright ) sobre el artículo publicado y favorece y permite la difusión del mismo bajo licencia Creative Commons Reconocimiento-CompartirIgual 4.0 Internacional (CC BY-SA 4.0). Esta licencia permite copiar, usar, difundir, transmitir y exponer públicamente el artículo, siempre que siempre que se cite la autoría y la publicación inicial en Anales del Sistema Sanitario de Navarra, y se distinga la existencia de esta licencia de uso.
